Clinical publications

Behavioural

Specific Cognitive Benefits

Functional

General Efficacy

---

Behavioural

Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment
Cummings JL, Schneider E, Tariot PN, Graham SM Neurology 2006; 67(1):57-63.

Improvement in behavioural symptoms in patients with moderate to severe Alzheimer’s disease by memantine: a pooled data analysis
Gauthier S, Loft H, Cummings J. Int J Geriatr Psychiatry 2008; 23: 537–545.

Memantine for Agitation/Aggression and Psychosis in Moderately Severe to Severe Alzheimer's Disease: A Pooled Analysis of 4 Studies
Wilcock GK, Ballard CG, Cooper JA, Loft H. J Clin Psychiatry. 2008 Mar;69(3):341-8

Evaluation of the Impact of Memantine Treatment
Vidal JS, Lacombe JM, Dartigues JF, Pasquier F, Robert P, Tzourio C, Alpérovitch A. Neuroepidemiology 2008;31:193–200

---

Specific Cognitive benefits

Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis
Schmitt FA, van Dyck CH, Wichems CH, Olin JT. Alzheimer Dis Assoc Disord 2006; 20(4):255-262

Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial
Pomara N, Ott BR, Peskind E, Resnick EM. Alzheimer Dis Assoc Disord 2007; 21(1):60-64

Pooled Analyses on Cognitive Effects of Memantine in Patients with Moderate to Severe Alzheimer’s Disease
Emre M, Mecocci P, Stender K Journal of Alzheimer’s Disease 2008; 14: 193–199

Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies
Mecocci P, Bladström A and Stender K, Int J Geriatr Psychiatry 2009; 24: 532-538

---

Functional

Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment
Feldman HH, Schmitt FA, Olin JT. Alzheimer Dis Assoc Disord 2006; 20(4):263-268

Memantine enhances autonomy in moderate to severe Alzheimer’s disease
Rive B, Vercelletto M, Damier FD, Cochran Jand Franc¸ois C.Int J Geriatr Psychiatry 2004; 19: 458–464.

---

General efficacy

Tolerability of switching from donepezil to memantine treatment in patients with moderate to severe Alzheimer’s disease
Waldemar G, Hyvärinen M, Josiassen MK, Kørner A, Lehto H,Wetterberg P. Int J Geriatr Psychiatry (2008)

A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease
Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ Arch Neurol 2006; 63(1):49-54

Memantine (Ebixa) in Clinical Practice – Results of an Observational Study
Calabrese P, Essner U, Förstl H. Dement Geriatr Cogn Disord 2007;24:111–117

Memantine in Moderate to Severe Alzheimer's Disease: a Meta-Analysis of Randomised Clinical Trials
Winblad B, Jones RW, Wirth Y, Stoffler A, Mobius HJ Dement Geriatr Cogn Disord 2007; 24(1):20-27

Memantine in Moderate to Severe Alzheimer's disease
Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. N Engl J Med 2003; 348(14):1333-1341.

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial
Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. JAMA 2004; 291(3):317-324.

Meta-analysis of six-month memantine trials in ADDoody R. Alzheimer's & Dementia 3, 7-17. 2007.

Reduction of Phosphorylated Tau during Memantine Treatment of Alzheimer’s Disease
Gunnarson MD, Kilander L, Basun H, Lannfelt L, Dement Geriatr Cogn Disord 2007;24:247–252

Resource Utilisation and Cost Analysis of Memantine in Patients with Moderate to Severe Alzheimer’s Disease
Wimo A, Winblad B, Stöffler A, Wirth Y, Möbius HJ. Pharmacoeconomics 2003; 21 (5): 1-14

Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease
Jones RW, Bayer A, Inglis F, Barker A, Phul R. Int J Geriatr Psychiatry 2007; 22(3):258-262

A review comparing the safety and tolerability of memantine with the acetylcholinesterase inhibitors
Jones RW., Int J Geriatr Psychiatry 2010.

Long-term Course and Effectiveness of Combination Therapy in Alzheimer Disease
Atri A, Shaughnessy LW, Locascio JJ, Growdon J, Alzheimer Dis Assoc Disord 2008; 22: 209–221

Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease
Lopez OL, Becker JT, Wahed AS, Saxton J, Sweet RA, Wolk DA, Klunk W, DeKosky ST,  J Neurol Neurosurg Psychiatry 2009; 80(6):600-607.

Analysis of the Effect of Memantine in Reducing the Worsening of Clinical Symptoms in Patients with Moderate to Severe Alzheimer's Disease
Wilkinson D, Andersen HF. Dement Geriatr Cogn Disord 2007;24:138–145